tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Armitage JM et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. 1991 Transplant. Proc. pmid:1703336
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Wiederrecht G et al. FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1704127
Ziccardi VB et al. Maxillofacial considerations in orthotopic liver transplantation. 1991 Oral Surg. Oral Med. Oral Pathol. pmid:1704494
Bierer BE et al. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. 1991 Eur. J. Immunol. pmid:1705513
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Sigal NH et al. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. 1991 Transplant. Proc. pmid:1712132
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Liu J et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. 1991 Cell pmid:1715244
Henderson DJ et al. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. 1991 Immunology pmid:1715317
Fujino Y et al. FK506 treatment of S-antigen induced uveitis in primates. 1991 Curr. Eye Res. pmid:1717199
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Moutabarrik A et al. In vitro FK506 kidney tubular cell toxicity. 1992 Transpl. Int. pmid:14621743
Moutabarrik A et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. 1992 Transpl. Int. pmid:14621744
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Lee C et al. FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. 1992 Biochem. Biophys. Res. Commun. pmid:1371677
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Galat A et al. A rapamycin-selective 25-kDa immunophilin. 1992 Biochemistry pmid:1371698
Metcalfe S et al. FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes. 1992 Transpl. Int. pmid:14621863
Hanawa H et al. An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. 1992 Clin. Immunol. Immunopathol. pmid:1371730
Japanese study of kidney transplantation: 1. Results of early phase II study. 1992 Transpl. Int. pmid:14621866
Hiraoka Y et al. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. 1992 J. Pharmacol. Exp. Ther. pmid:1372051
Chen TS et al. Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 J. Antibiot. pmid:1372307
Morisaki M and Arai T Identity of immunosuppressant FR-900520 with ascomycin. 1992 J. Antibiot. pmid:1372308
Doi R et al. Effects of FK506 on exocrine pancreas in rats. 1992 Pancreas pmid:1372739
Furukawa H et al. The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. 1992 Transplantation pmid:1373531
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
Lepre CA et al. Solution structure of FK506 bound to FKBP-12. 1992 FEBS Lett. pmid:1375171
Ruff VA et al. FKBP-12 is not an inhibitor of protein kinase C. 1992 Immunol. Invest. pmid:1375189
Kawaguchi S [Effects of FK506 on aminonucleoside-induced nephrotic rats]. 1992 Nihon Jinzo Gakkai Shi pmid:1375300
Sigal NH and Dumont FJ Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. 1992 Annu. Rev. Immunol. pmid:1375473
Chen TS et al. Microbial transformation of immunosuppressive compounds. II. Specific desmethylation of 13-methoxy group of FK 506 and FR 900520 by an unidentified Actinomycete ATCC 53828 [corrected]. 1992 J. Antibiot. pmid:1375593
Meingassner JG and Stütz A Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? 1992 J. Invest. Dermatol. pmid:1375617
Schneck FX et al. Pediatric renal transplantation under FK-506 immunosuppression. 1992 J. Urol. pmid:1375663
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Demetris AJ et al. Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. 1992 Lancet pmid:1376851
Ichihashi T et al. Haemolytic uraemic syndrome during FK506 therapy. 1992 Lancet pmid:1376852
O'Keefe SJ et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. 1992 Nature pmid:1377361
Clipstone NA and Crabtree GR Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. 1992 Nature pmid:1377362
Hasegawa S et al. Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. 1992 J. Thorac. Cardiovasc. Surg. pmid:1279319
Peattie DA et al. Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1279700
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hanke JH et al. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. 1992 Lymphokine Cytokine Res. pmid:1281674
Logan TM et al. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments. 1992 FEBS Lett. pmid:1281793
Bergstrand H et al. Modulation of neutrophil superoxide generation by inhibitors of protein kinase C, calmodulin, diacylglycerol and myosin light chain kinases, and peptidyl prolyl cis-trans isomerase. 1992 J. Pharmacol. Exp. Ther. pmid:1281879
DiLella AG et al. Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. 1992 Biochem. Biophys. Res. Commun. pmid:1281998
Sawada M et al. Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. 1992 Biochem. Biophys. Res. Commun. pmid:1282000
Minoda M et al. Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. 1992 Microbiol. Immunol. pmid:1282197
Min DI et al. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. 1992 Am J Hosp Pharm pmid:1282779
Mochizuki M [Immunotherapy in ocular diseases]. 1992 Nippon Ganka Gakkai Zasshi pmid:1283052
Kumano K et al. [Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators]. 1992 Nippon Hinyokika Gakkai Zasshi pmid:1379657
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Yoshimura R et al. A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. 1992 Transplant. Proc. pmid:1379755
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Wada H et al. Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. 1992 Transplant. Proc. pmid:1379758
Cai X et al. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. 1992 Transplant. Proc. pmid:1379759
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Friccius H et al. The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. 1992 Int. J. Immunopharmacol. pmid:1380951
Dumont FJ et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. 1992 J. Exp. Med. pmid:1380976
Norris AA et al. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. 1992 Clin. Exp. Immunol. pmid:1381297
Karpas A et al. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1381509
Yatscoff RW and Shaw LM Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. 1992 Ther Drug Monit pmid:1381530
Arceci RJ et al. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. 1992 Blood pmid:1381629
Pahl A and Keller U FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. 1992 J. Bacteriol. pmid:1381710
Takahashi N [Cyclophilin and FK506-binding protein]. 1992 Seikagaku pmid:1381737
Lee TK et al. Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. 1992 J. Surg. Res. pmid:1382152
Siekierka JJ and Sigal NH FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. 1992 Curr. Opin. Immunol. pmid:1384551
Hultsch T et al. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. 1992 Mol. Biol. Cell pmid:1384815
Petros AM et al. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. 1992 J. Biomol. NMR pmid:1384850
Liu J et al. The effects of FK-506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6. 1992 Int. Arch. Allergy Immunol. pmid:1384862
Mochizuki M et al. Preclinical and clinical study of FK506 in uveitis. 1992 Curr. Eye Res. pmid:1385045
Chung J et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. 1992 Cell pmid:1377606
Xu RX et al. Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants. 1992 FEBS Lett. pmid:1377648
Petros AM et al. NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. 1992 J. Med. Chem. pmid:1377749